keyword
MENU ▼
Read by QxMD icon Read
search

zoledronic

keyword
https://www.readbyqxmd.com/read/28429148/an-observational-time-and-motion-study-of-denosumab-subcutaneous-injection-and-zoledronic-acid-intravenous-infusion-in-patients-with-metastatic-bone-disease-results-from-three-european-countries
#1
Jean-Jacques Body, Francesca Gatta, Erwin De Cock, Sunning Tao, Persefoni Kritikou, Pauline Wimberger, Jeroen Mebis, Marc Peeters, Paolo Pedrazzoli, Augusto Caraceni, Vincenzo Adamo, Guy Hechmati
PURPOSE: Denosumab (administered via subcutaneous injection) demonstrated superior efficacy versus the intravenously administered zoledronic acid in the prevention of skeletal-related events in an integrated analysis of three head-to-head phase III trials in patients with bone metastases secondary to solid tumors. To date, no studies have evaluated treatment administration duration endpoints of these two agents. METHODS: A multinational, multi-site, observational time and motion study conducted in 10 day oncology units (DOUs) across Belgium, Germany, and Italy...
April 21, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28429052/the-skeletal-impact-of-the-chemotherapeutic-agent-etoposide
#2
A J Koh, B P Sinder, P Entezami, L Nilsson, L K McCauley
Effects of the chemotherapeutic agent etoposide on the skeleton were determined in mice. Numbers of bone marrow cells were reduced and myeloid cells were increased. Bone volume was significantly decreased with signs of inhibition of bone formation. Etoposide after pre-treatment with zoledronic acid still reduced bone but overall bone volume was higher than with etoposide alone. INTRODUCTION: Chemotherapeutics target rapidly dividing tumor cells yet also impact hematopoietic and immune cells in an off target manner...
April 20, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28414206/wenshen-zhuanggu-formula-effectively-suppresses-breast-cancer-bone-metastases-in-a-mouse-xenograft-model
#3
Jia-Jia Li, Wei-Ling Chen, Jian-Yi Wang, Qian-Wen Hu, Zhen-Ping Sun, Shuai Zhang, Sheng Liu, Xiang-Hui Han
Wenshen Zhuanggu formula (WSZG) is a traditional Chinese medicine used as an adjuvant for the prevention of bone metastases in breast cancer patients. In this study we investigated the efficacy of WSZG in preventing bone metastases and the potential mechanisms in a mouse xenograft model of breast cancer bone metastases. This model was established by injection of human MDA-MB-231BO-Luc breast cancer cells alone or a mixture of the cancer cells with bone marrow-derived mesenchymal stem cells (BMSCs) into left ventricle of the heart in female nude mice...
April 17, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/28412218/evaluation-of-the-combined-use-of-metronomic-zoledronic-acid-and-coriolus-versicolor-in-intratibial-breast-cancer-mouse-model
#4
Chun-Hay Ko, Grace Gar-Lee Yue, Si Gao, Ke-Wang Luo, Wing-Sum Siu, Wai-Ting Shum, Hoi-Ting Shiu, Julia Kin-Ming Lee, Gang Li, Ping-Chung Leung, Andreas Evdokiou, Clara Bik-San Lau
ETHNOPHARMACOLOGICAL RELEVANCE: Coriolus versicolor (CV) is a mushroom traditionally used for strengthening the immune system and nowadays used as immunomodulatory adjuvant in anticancer therapy. Breast cancer usually metastasizes to the skeleton, interrupts the normal bone remodeling process and causes osteolytic bone lesions. The aims of the present study were to evaluate its herb-drug interaction with metronomic zoledronate in preventing cancer propagation, metastasis and bone destruction...
April 12, 2017: Journal of Ethnopharmacology
https://www.readbyqxmd.com/read/28405500/zoledronate-can-induce-colorectal-cancer-microenvironment-expressing-btn3a1-to-stimulate-effector-%C3%AE-%C3%AE-t-cells-with-antitumor-activity
#5
Maria Raffaella Zocchi, Delfina Costa, Roberta Venè, Francesca Tosetti, Nicoletta Ferrari, Simona Minghelli, Roberto Benelli, Stefano Scabini, Emanuele Romairone, Silvia Catellani, Aldo Profumo, Alessandro Poggi
Amino-bis-phosphonates (N-BPs) such as zoledronate (Zol) have been used in anticancer clinical trials due to their ability to upregulate pyrophosphate accumulation promoting antitumor Vγ9Vδ2 T cells. The butyrophilin 3A (BTN3A, CD277) family, mainly the BTN3A1 isoform, has emerged as an important structure contributing to Vγ9Vδ2 T cells stimulation. It has been demonstrated that the B30.2 domain of BTN3A1 can bind phosphoantigens (PAg) and drive the activation of Vγ9Vδ2 T cells through conformational changes of the extracellular domains...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28399247/zoledronic-acid-dosing-interval-for-metastatic-cancer-reply
#6
LETTER
Andrew L Himelstein, Charles L Loprinzi, Charles L Shapiro
No abstract text is available yet for this article.
April 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28399243/zoledronic-acid-dosing-interval-for-metastatic-cancer
#7
LETTER
Marcello Tucci, Consuelo Buttigliero, Massimo Di Maio
No abstract text is available yet for this article.
April 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28399242/zoledronic-acid-dosing-interval-for-metastatic-cancer
#8
LETTER
Tetsuya Tanimoto, Kenji Tsuda, Jinichi Mori
No abstract text is available yet for this article.
April 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28392837/denosumab-treatment-in-the-management-of-patients-with-advanced-prostate-cancer-clinical-evidence-and-experience
#9
REVIEW
Miriam Hegemann, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Osteoprotective therapies have become an essential component in the management of advanced prostate cancer (PC) patients as bone metastases (BMs) have a major impact on morbidity and mortality. Denosumab is a fully humanized antibody targeting the receptor activator of nuclear factor κB ligand (RANKL), which has been approved by the European Medicines Agency (EMA) in Europe and the United States (US) Food and Drug Administration (FDA) in the US for prevention of skeletal-related events (SREs) in patients with solid tumors and BMs, including PC...
March 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28390132/a-5-year-retrospective-longitudinal-study-on-the-incidence-and-the-risk-factors-of-osteonecrosis-of-the-jaws-in-patients-treated-with-zoledronic-acid-for-bone-metastases-from-solid-tumors
#10
M Manfredi, G Mergoni, M Goldoni, S Salvagni, E Merigo, M Meleti, P Vescovi
BACKGROUND: The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. METHODS: This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms...
April 8, 2017: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/28390131/radiodensitometric-study-for-evaluation-of-bone-mineral-density-around-dental-implants-after-zoledronic-acid-treatment-in-ovariectomized-rats
#11
S Dikicier, E Dikicier, U Karacayli, B Erguder
BACKGROUND: The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats. MATERIAL AND METHODS: 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy...
April 8, 2017: Medicina Oral, Patología Oral y Cirugía Bucal
https://www.readbyqxmd.com/read/28382583/use-and-safety-of-denosumab-in-cancer-patients
#12
Alba Manzaneque, Cristian Chaguaceda, Mireia Mensa, Carla Bastida, Natàlia Creus-Baró
Background Few data have been reported on the use and safety of denosumab in patients with solid tumors and bone metastasis in clinical practice. Objectives To describe the use of denosumab and to analyze its adverse effects (AE) in tertiary hospital cancer outpatients. Methods Retrospective study of patients who started denosumab between January 2013 and June 2015. We recorded demographic, clinical, and treatment-related variables, as well as the reasons for discontinuation and AE. Results The study population comprised 104 patients, of whom 86 (82...
April 5, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28365529/giant-cell-tumour-of-bone-in-the-denosumab-era
#13
REVIEW
Lizz van der Heijden, P D Sander Dijkstra, Jean-Yves Blay, Hans Gelderblom
Giant cell tumour of bone (GCTB) is an intermediate locally aggressive primary bone tumour, occurring mostly at the meta-epiphysis of long bones. Overexpression of receptor activator of nuclear factor kappa-B ligand (RANKL) by mononuclear neoplastic stromal cells promotes recruitment of numerous reactive multinucleated osteoclast-like giant cells, causing lacunar bone resorption. Preferential treatment is curettage with local adjuvants such as phenol, alcohol or liquid nitrogen. The remaining cavity may be filled with bone graft or polymethylmethacrylate (PMMA) bone cement; benefits of the latter are a lower risk of recurrence, possibility of direct weight bearing and early radiographic detection of recurrences...
March 30, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28356569/synergistic-targeting-of-breast-cancer-stem-like-cells-by-human-%C3%AE-%C3%AE-t-cells-and-cd8-t-cells
#14
Hung-Chang Chen, Noémie Joalland, John S Bridgeman, Fouad S Alchami, Ulrich Jarry, Mohd Wajid A Khan, Luke Piggott, Yasmin Shanneik, Jianqiang Li, Marco J Herold, Thomas Herrmann, David A Price, Awen M Gallimore, Richard W Clarkson, Emmanuel Scotet, Bernhard Moser, Matthias Eberl
The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC restricted γδ T cells and antigen-specific CD8(+) T cells. Stable lines with characteristics of breast CSC-like cells were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their CD44(hi) CD24(lo) GD2(+) phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non-adherent conditions, as well as their potent tumorigenicity, self-renewal and differentiation in xenografted mice...
March 30, 2017: Immunology and Cell Biology
https://www.readbyqxmd.com/read/28345127/zoledronate-promotes-bone-formation-by-blocking-osteocyte-osteoblast-communication-during-bone-defect-healing
#15
Pingping Cui, Hongrui Liu, Jing Sun, Norio Amizuka, Qinfeng Sun, Minqi Li
Nitrogen-containing bisphosphonates (N-BPs) are potent antiresorptive drugs and their actions on osteoclasts have been studied extensively. Recent studies have suggested that N-BPs also target bone-forming cells. However, the precise mechanism of N-BPs in osteoblasts is paradoxical, and the specific role of osteocytes is worthy of in-depth study. Here, we investigated the cellular mechanisms of N-BPs regulating bone defect healing by zoledronate (ZA). Bone histomorphometry confirmed an increase in new bone formation by systemic ZA administration...
March 27, 2017: Histology and Histopathology
https://www.readbyqxmd.com/read/28344861/zoledronic-acid-boosts-%C3%AE-%C3%AE-t-cell-activity-in-children-receiving-%C3%AE-%C3%AE-t-and-cd19-cell-depleted-grafts-from-an-hla-haplo-identical-donor
#16
A Bertaina, A Zorzoli, A Petretto, G Barbarito, E Inglese, P Merli, C Lavarello, L P Brescia, B De Angelis, G Tripodi, L Moretta, F Locatelli, I Airoldi
We demonstrated that γδ T cells of patients given HLA-haploidentical HSCT after removal of αβ(+) T cells and CD19(+) B cells are endowed with the capacity of killing leukemia cells after ex vivo treatment with zoledronic acid (ZOL). Thus, we tested the hypothesis that infusion of ZOL in patients receiving this type of graft may enhance γδ T-cell cytotoxic activity against leukemia cells. ZOL was infused every 28 d in 43 patients; most were treated at least twice. γδ T cells before and after ZOL treatments were studied in 33 of these 43 patients, till at least 7 mo after HSCT by high-resolution mass spectrometry, flow-cytometry, and degranulation assay...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28339664/adult-paget-s-disease-of-bone-a-review
#17
Stephen Paul Tuck, Robert Layfield, Julie Walker, Babitha Mekkayil, Roger Francis
Adult PD of bone is the second commonest metabolic bone condition after osteoporosis. The condition is characterized by increased bone cell activity, with bone-resorbing osteoclasts often larger and containing more nuclei than normal, and osteoblasts producing increased amounts of disorganized bone. This leads to expanded bone of poor quality possessing both sclerotic and lytic areas. PD of bone has a strong genetic element, with a family history being noted in 10-20% of cases. A number of genetic defects have been found to be associated with the condition...
February 17, 2017: Rheumatology
https://www.readbyqxmd.com/read/28326300/the-efficacy-of-bisphosphonates-for-prevention-of-osteoporotic-fracture-an-update-meta-analysis
#18
Ji-Hye Byun, Sunmee Jang, Sumin Lee, Suyeon Park, Hyun Koo Yoon, Byung-Ho Yoon, Yong-Chan Ha
BACKGROUND: The efficacy of bisphosphonates for osteoporotic fracture has been consistently reported in recent randomized controlled trials (RCTs) enrolling hundreds of patients. The objective of this study was to update knowledge on the efficacy of available bisphosphonates in the prevention of vertebral and non-vertebral fractures. METHODS: An approach "using systematic reviews" on PubMed and Cochrane Library was taken. Twenty-four RCTs investigating the effects of bisphosphonates for the prevention of osteoporotic fracture were included in final analysis...
February 2017: Journal of Bone Metabolism
https://www.readbyqxmd.com/read/28324132/erratum-to-cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#19
K Moriwaki, M Mouri, H Hagino
No abstract text is available yet for this article.
March 21, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28324123/long-term-bone-scintigraphy-results-after-intravenous-zoledronate-in-paget-s-disease-of-bone
#20
Ian R Reid, Katherine Maslowski
Zoledronate produces long-term normalization of biochemical markers in Paget's disease but whether this implies the absence of active disease is unknown. We have determined whether bone scintigraphy, a more sensitive index of disease activity, is also normalized ≥5 years after treatment with zoledronate. A consecutive case series of 11 individuals with Paget's disease treated with zoledronate 5 mg ≥5 years previously is reported. Eight patients received a single zoledronate infusion and were assessed 55-120 months later...
March 21, 2017: Calcified Tissue International
keyword
keyword
113547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"